Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer.
Moutafi MK, Molero M, Martinez Morilla S, Baena J, Vathiotis IA, Gavrielatou N, Castro-Labrador L, de Garibay GR, Adradas V, Orive D, Valencia K, Calvo A, Montuenga LM, Ponce Aix S, Schalper KA, Herbst RS, Paz-Ares L, Rimm DL, Zugazagoitia J.
Moutafi MK, et al. Among authors: martinez morilla s.
J Immunother Cancer. 2022 Aug;10(8):e004757. doi: 10.1136/jitc-2022-004757.
J Immunother Cancer. 2022.
PMID: 36002182
Free PMC article.